Patents by Inventor Mandeep Kaur

Mandeep Kaur has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240086934
    Abstract: Disclosed is a system and method for identifying various combinations of parcels of land with sufficient transmission, resources, market demand, and available land to build a wind farm or solar farm. Different criteria associated with each parcel of land include land characteristics including size, ownership, tree coverage, elevations, terrain, buildable land, transmission characteristics including substation hardware costs, network upgrades, general tie-in costs, market characteristics including historical locational marginal pricing (LMPs), and resource characteristics including net capacity factor (NCF) of wind or solar. In one example, the present invention identifies clusters of land parcels that minimize the number of land owners, maximize buildable land, minimize transmission cost, maximize NCF, and maximize nodal LMPs.
    Type: Application
    Filed: September 9, 2022
    Publication date: March 14, 2024
    Inventors: Aaron P. BLOOM, Keith J. HARDING, Caitlin A. JOHNSON, David W. ABEL, Mandeep KAUR, Timothy D. STOVALL, Timothy J. KUDALIS, Taran RAJ, Douglas B. SHAFFER, Benjamin D. GRINDY
  • Publication number: 20220096529
    Abstract: A method including the step of administering 2-hydroxypropyl-?-cyclodextrin (HP?CD) for use in the treatment of breast cancer. Particularly, this invention relates to HP?CD for use in the treatment of triple negative breast cancer, wherein the HP?CD is for administration to a patient in need thereof. The invention extends to methods of preparing a pharmaceutical composition comprising HP?CD, and further extends to a method of treating breast cancer, typically triple negative breast cancer, by administration of the composition to a patient in need thereof.
    Type: Application
    Filed: January 28, 2020
    Publication date: March 31, 2022
    Applicant: UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURG
    Inventors: Mandeep KAUR, Sourav Taru SAHA
  • Patent number: 10485769
    Abstract: In one embodiment, the invention provides methods of treatment which use therapeutically effective amounts of Cholesteryl Ester Transfer Protein (CETP) inhibitors to treat a variety of cancers. In certain embodiments, the inhibitor is a CETP-inhibiting small molecule, CETP-inhibiting antisense oligonucleotide, CETP-inhibiting siRNA or a CETP-inhibiting antibody. Related pharmaceutical compositions, kits, diagnostics and screens are also provided.
    Type: Grant
    Filed: February 23, 2016
    Date of Patent: November 26, 2019
    Assignee: King Abdullah University of Science and Technology
    Inventors: Mandeep Kaur, Luke E. Esau, Sunil Sagar
  • Patent number: 9914974
    Abstract: Embodiments of the present invention concern methods and compositions related to detection of ovarian cancer, including detection of the stage of ovarian cancer, in some cases. In particular, the invention encompasses use of expression of TFAP2A and in some embodiments CA125 and/or E2F5 to identify ovarian cancer, including detecting mRNA and/or protein levels of the respective gene products. Kits for detection of ovarian cancer are also described.
    Type: Grant
    Filed: June 9, 2015
    Date of Patent: March 13, 2018
    Assignee: King Abdullah University of Science and Technology
    Inventors: Vladimir Bajic, Mandeep Kaur
  • Publication number: 20180049997
    Abstract: In one embodiment, the invention provides methods of treatment which use therapeutically effective amounts of Cholesteryl Ester Transfer Protein (CETP) inhibitors to treat a variety of cancers. In certain embodiments, the inhibitor is a CETP-inhibiting small molecule, CETP-inhibiting antisense oligonucleotide, CETP-inhibiting siRNA or a CETP-inhibiting antibody. Related pharmaceutical compositions, kits, diagnostics and screens are also provided.
    Type: Application
    Filed: February 23, 2016
    Publication date: February 22, 2018
    Inventors: Mandeep Kaur, Luke E. Esau, Sunil Sagar
  • Patent number: 9890106
    Abstract: Derivatives of plumbagin can be selectively cytotoxic to breast cancer cells. Derivative ‘A’ (Acetyl Plumbagin) has emerged as a lead molecule for testing against estrogen positive breast cancer and has shown low hepatotoxicity as well as overall lower toxicity in nude mice model. The toxicity of derivative ‘A’ was determined to be even lower than vehicle control (ALT and AST markers). The possible mechanism of action identified based on the microarray experiments and pathway mapping shows that derivative ‘A’ could be acting by altering the cholesterol-related mechanisms. The low toxicity profile of derivative ‘A’ highlights its possible role'as future anti-cancer drug and/or as an adjuvant drug to reduce the toxicity of highly toxic chemotherapeutic'drugs.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: February 13, 2018
    Assignee: KING ABDULLAH UNIVERSITY OF SCIENCE & TECHNOLOGY
    Inventors: Sunil Sagar, Mandeep Kaur, Luke E. Esau
  • Patent number: 9740563
    Abstract: Controlling a software process by causing the execution of a first software process on a computer, where the first software process is configured to exclusively access a resource on the computer, causing the execution of a second software process on the computer when the first software process has exclusive access to the resource, where the second software process is configured to perform a first predefined action that is independent of the second software process accessing the resource, attempt to access the resource, and perform a second predefined action that is dependent on the second software process accessing resource, and causing the first software process to terminate its exclusive access to the resource, thereby causing the second software process to access the resource and perform the second predefined action.
    Type: Grant
    Filed: May 24, 2013
    Date of Patent: August 22, 2017
    Assignee: International Business Machines Corporation
    Inventors: Mandeep Kaur Jandir, Limor Provizor, Mark L. Yakushev, Asaf Yeger
  • Publication number: 20150368620
    Abstract: In one aspect, a method for detaching adherent cells can include adding a cell lifting solution to the media including a sample of adherent cells and incubating the sample of adherent cells with the cell lifting solution. No scraping or pipetting is needed to facilitate cell detachment. The method do not require inactivation of cell lifting solution and no washing of detaching cells is required to remove cell lifting solution. Detached cells can be stained with dye in the presence of cell lifting solution and are further analyzed using flow cytometer. The method has been tested using 6 different cell lines, 4 different assays, two different plate formats (96 and 384 well plates) and two different flow cytometry instruments. The method is simple to perform, less time consuming, with no cell loss and makes high throughput flow cytometry on adherent cells a reality.
    Type: Application
    Filed: January 29, 2014
    Publication date: December 24, 2015
    Inventors: Mandeep Kaur, Luke E. Esau
  • Publication number: 20150284809
    Abstract: Embodiments of the present invention concern methods and compositions related to detection of ovarian cancer, including detection of the stage of ovarian cancer, in some cases. In particular, the invention encompasses use of expression of TFAP2A and in some embodiments CA125 and/or E2F5 to identify ovarian cancer, including detecting mRNA and/or protein levels of the respective gene products. Kits for detection of ovarian cancer are also described.
    Type: Application
    Filed: June 9, 2015
    Publication date: October 8, 2015
    Applicant: KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY
    Inventors: Vladimir Bajic, Mandeep Kaur
  • Patent number: 9057107
    Abstract: Embodiments of the present invention concern methods and compositions related to detection of ovarian cancer, including detection of the stage of ovarian cancer, in some cases. In particular, the invention encompasses use of expression of TFAP2A and in some embodiments CA125 and/or E2F5 to identify ovarian cancer, including detecting mRNA and/or protein levels of the respective gene products. Kits for detection of ovarian cancer are also described.
    Type: Grant
    Filed: March 8, 2012
    Date of Patent: June 16, 2015
    Assignee: King Abdullah University of Science and Technology
    Inventors: Vladimir Bajic, Mandeep Kaur
  • Publication number: 20140351822
    Abstract: Controlling a software process by causing the execution of a first software process on a computer, where the first software process is configured to exclusively access a resource on the computer, causing the execution of a second software process on the computer when the first software process has exclusive access to the resource, where the second software process is configured to perform a first predefined action that is independent of the second software process accessing the resource, attempt to access the resource, and perform a second predefined action that is dependent on the second software process accessing resource, and causing the first software process to terminate its exclusive access to the resource, thereby causing the second software process to access the resource and perform the second predefined action.
    Type: Application
    Filed: May 24, 2013
    Publication date: November 27, 2014
    Applicant: INTERNATIONAL BUSINESS MACHINES CORPORATION
    Inventors: Mandeep Kaur Jandir, Limor Provizor, Mark L. Yakushev, Asaf Yeger
  • Publication number: 20120231090
    Abstract: Embodiments of the present invention concern methods and compositions related to detection of ovarian cancer, including detection of the stage of ovarian cancer, in some cases. In particular, the invention encompasses use of expression of TFAP2A and in some embodiments CA125 and/or E2F5 to identify ovarian cancer, including detecting mRNA and/or protein levels of the respective gene products. Kits for detection of ovarian cancer are also described.
    Type: Application
    Filed: March 8, 2012
    Publication date: September 13, 2012
    Inventors: Vladimir Bajic, Mandeep Kaur